Method for reducing the risk, lessening the symptom, or delaying the onset of insulin resistance by administering SS-31
View Patent ↗The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2 a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.
1. A method for reducing the risk, lessening the symptoms, or delaying the outset of insulin resistance in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutically effective amount of the peptide D-Arg-2′6′Dmt-Lys-Phe-NH 2 (SS-31).
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the subject is suffering from diet-induced insulin resistance.
4. The method of claim 1 , wherein the insulin resistance is associated with type II diabetes.
5. The method of claim 1 , wherein the insulin resistance is associated with obesity.
6. The method of claim 1 , wherein the insulin resistance is associated with coronary artery disease, renal dysfunction, atherosclerosis, hyperlipidemia, essential hypertension, or fatty liver.
7. The method of claim 1 , wherein the insulin resistance is drug-induced insulin resistance.
8. The method of claim 1 , wherein the peptide is administered prior to the onset of type II diabetes.
9. The method of claim 1 , wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, or intramuscularly.
10. The method of claim 1 , further comprising the step of identifying the mammalian subject in need of a therapeutically effective amount of the peptide D-Arg-2′6′Dmt-Lys-Phe-NH 2 (SS-31).
11. The method of claim 1 , further comprising monitoring the mammalian subject for the therapeutic effects of the peptide D-Arg-2′6′Dmt-Lys-Phe-NH 2 (SS-31).
12. The method of claim 1 , wherein the therapeutically effective amount of the peptide D-Arg-2′6′Dmt-Lys-Phe-NH 2 (SS-31) provides a concentration of peptide in a target tissue of about 10 −8 to 10 −6 molar.